Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Technical, and Others segments. Its ophthalmic medical devices are used for diagnosis, treatment, or surgeries, including vitreoretinal diseases, cataract, glaucoma, refractive surgery, ocular surface diseases, optometry, and pediatric ophthalmology. The Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, and ophthalmic disease diagnosis and treatment equipment and related supporting consumables. The Distribution segment sells diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment, and related supporting consumables. The Technical segment provides warranty services, maintenance services, and after-sales services related consumables. The Others segment engages in the provision of equipment leasing and agent registration services; and licensing intellectual properties. The company sells its products directly and through distributors to public and private hospitals, and other customers. Gaush Meditech Ltd. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Gaush Meditech Ltd

温州医科大学附属眼视光医院 provides comprehensive and quality eye health medical services, including prevention, diagnosis, treatment, rehabilitation, and healthcare, self-described as following a path of intrinsic development by offering superior services where others may not.

温州医科大学附属眼视光医院

成都爱迪眼科医院 is a national level three eye hospital that focuses on various eye diseases and corrective procedures.

成都爱迪眼科医院

高视医疗集团 specializes in the research, production, sales, training, and technical services of ophthalmic medical devices, self-described as having over twenty years of experience in the ophthalmology field.

Metric
Company Name	Gaush Meditech Ltd	温州医科大学附属眼视光医院	成都爱迪眼科医院
Symbol	2.41K
MSH ID	COM:GAUSH	CN:WZEYE	COM:028AIDI
Market	STOCKS	PRIVATE	PRIVATE
Sector		Healthcare & Health Services	Healthcare & Health Services
Industry		Medical Services	Healthcare
Country	CN	CN	CN
Stage
Employee Count	869
Website	gaush.com	wzeye.cn	028aidi.com
LinkedIn			%E6%88%90%E9%83%BD%E7%88%B1%E8%BF%AA%E7%9C%BC%E7%A7%91%E5%8C%BB%E9%99%A2%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Founders

Metric
Market Cap	217.58M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	193.42M
Revenue (LTM)
Revenue (NTM)
Gross Profit	95.13M
EBITDA	50.91M
Operating Income	40.46M
Net Income	23.87M
EPS	0.16
Diluted EPS	0.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.49
Operating Profit Margin	0.21
EBITDA Margin	0.26
Net Profit Margin	0.12
Return on Equity	0.11
Return on Assets	0.06
Return on Capital Employed	0.15

2407

COM:GAUSH

高视医疗集团

Last Close

9.81

25/11 07:59

Market Cap

1.69B

Beta: -

Volume Today

601.30K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.65
EV Multiple	7.70

Metric
Days Sales Outstanding
Days Payables Outstanding	46.26
Days Inventory Outstanding	218.38
Operating Cycle	269.92
Cash Conversion Cycle	209.72
Asset Turnover	0.49

Metric
Operating Cash Flow	34.25M
Free Cash Flow	27.98M
Cash Flow to Debt	0.37
Operating Cash Flow/Sales	0.18
Free Cash Flow Yield	0.14

Metric
Cash & Equivalents	85.10M
Accounts Receivable	2.71M
Inventory	45.19M
Goodwill	132.24M
Debt to Capitalization	0.28
Debt to Assets	0.23
Current Ratio	1.56
Quick Ratio	1.38

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.04
SG&A to Revenue	0.09